GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Defining the role of aberrant signal pathway activation in melanoma on the immune microenvironment

$51,036
Amanda Truong · University Of Utah · F30 · FY2021 · CA

Characterizing the DPP8/9 Pyroptotic Checkpoint with Chemoproteomic Protease Substrate Profiling

$51,036
Andrew Griswold · Weill Medical Coll Of Cornell Univ · F30 · FY2021 · CA

Identifying the Role of Tumor Cell Intrinsic DNMT1 in Anti-Tumor Immunity in Pancreatic Ductal Adenocarcinoma

$51,036
Erin Elizabeth Hollander · University Of Pennsylvania · F30 · FY2021 · CA

Function of IRF8 in T cell activation and immune tolerance

$51,036
John David Klement · Augusta University · F30 · FY2021 · CA

Exploring the Innate Sensors Underlying Cancer Immunosurveillance

$51,036
Daniel J Kim · Yale University · F30 · FY2021 · CA

Elucidating the protective role of stromal fibrosis to radiation-induced tumor immunity

$51,036
Varintra Edlyn Lander · Washington University · F30 · FY2021 · CA

Validation of WEE1 kinase as a clinical target in KRAS-mutant pancreatic cancer

$51,036
John Nathaniel Diehl · Univ Of North Carolina Chapel Hill · F30 · FY2021 · CA

Uncovering interactions of the gut microbiome with the immune system in the context of immune checkpoint inhibitors

$51,036
Jennifer Chung · University Of Connecticut Sch Of Med/Dnt · F30 · FY2021 · CA

Impact of local and systemic cellular senescence toward Triple Negative Breast Cancer growth and drug therapy

$51,036
Irfan Khan · Georgetown University · F30 · FY2021 · CA

Mechanistic Dissection and Therapeutic Targeting of B7x in Cancer

$51,036
Christopher D Nishimura · Albert Einstein College Of Medicine · F30 · FY2021 · CA

B7x in Cancer: Mechanisms and Therapies

$51,036
Peter John · Albert Einstein College Of Medicine · F30 · FY2021 · CA

GU Malignancies Research Program

$51,030
Nima Sharifi · Case Western Reserve University · P30 · FY2020 · CA

Developmental Therapeutics Research Program

$51,030
John James Letterio · Case Western Reserve University · P30 · FY2020 · CA

Chk1 and Chk2 in Human Cancer Cells

$50,860
Deborah F Wilsker · Johns Hopkins University · F32 · FY2009 · CA

Developmental Therapeutics Research Program

$50,794
John James Letterio · Case Western Reserve University · P30 · FY2018 · CA

Function of PD-1 Signaling on the Activity of B cells in the Tumor Microenvironment in Breast Cancer

$50,717
Xiaolu Pan · Univ Of North Carolina Chapel Hill · F31 · FY2025 · CA

Title: Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA in Combination with Immune Checkpoint Blockade

$50,521
Emmanuel T Akporiaye · Veana Therapeutics, Llc · R43 · FY2019 · CA

Function of IRF8 in T cell activation and immune tolerance

$50,520
John David Klement · Augusta University · F30 · FY2020 · CA

Augmenting Pancreatic Cancer Immunotherapy via TGFβ Pathway Inhibition

$50,520
Daniel R Principe · University Of Illinois At Chicago · F30 · FY2020 · CA

B7x in Cancer: Mechanisms and Therapies

$50,520
Peter John · Albert Einstein College Of Medicine · F30 · FY2020 · CA

Pglyrp3 cooperates with Snail1 to mediate anti-tumor immune response in breast cancer

$50,520
Mathew Sebastian · University Of Florida · F30 · FY2020 · CA

Modeling the Immune Response to Melanoma Brain Metastases in Mice

$50,520
Irina Krykbaeva · Yale University · F30 · FY2020 · CA

Defining the role of aberrant signal pathway activation in melanoma on the immune microenvironment

$50,520
Amanda Truong · University Of Utah · F30 · FY2020 · CA

CV301 and Anti-PD-1 Therapy in Non-Small Cell Lung Cancer

$50,506
Arun Rajan · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Research Program

$50,472
Olga Anczukow-Camarda · Jackson Laboratory · P30 · FY2024 · CA